ALSO NOTED: Squeaking hip devices worry patients, docs; Biotech M&A has yet to reach its peak;

> Replacement hips made with ceramic parts are squeaking in certain patients, some of which have sued Stryker; the company says the noisy side effect happens in less than 1 percent of implants. Surgeons worry that the squeaking signals possible structural problems. Report

> In analyzing the PowerShares Dynamic Biotech & Genome ETF, a fund made up of primarily small- and medium-cap biotech stocks, Seeking Alpha notes that Big Pharma's appetite for biotech acquisitions is far from satisfied. M&A report

> South Korea plans to boost its stockpile of drugs to fight avian flu in humans, securing enough doses to treat 2.5 million; though it didn't specify which antiviral, its health officials have named Roche's Tamiflu as a key treatment. Report

> Takeda Pharmaceuticals has hired the PR firm Fleishman-Hillard to help launch a new drug for Friedreich's Ataxia in Europe. Report

> Responding to HIV-positive critic, one Thai official promised that compulsory licensing is working; second-line treatments are already reaching patients in need. Report

> Novalar got the FDA's blessing on a drug antidote to dental anesthesia, which reverses the oral numbness after dental procedures are finished. Release

> India's Aurobindo Pharma got nine new-product nods in South Africa, bringing to 31 the number of products approved there. Report

> GlaxoSmithKline and Adolor's seemingly never-ending effort to win approval for Entereg has hit yet another delay. Entereg report

> Medical device maker NuVasive is buying Osteocel, Osiris' biologics business, for $35 million up front and an additional $50 million in milestone payments. Report

And Finally... Vaccine experts are pondering just how long vaccines will be able to provide immunity in a world where some diseases are all but eliminated and natural exposure to many common viruses has ended. Report

Suggested Articles

Patients with epithelioid sarcoma previously had no targeted treatment options, but that'll change with Epizyme's approval for Tazverik.

With federal prosecutors laying waste to Insys' executive team, one big domino was still left to fall: Founder and former CEO John Kapoor.

Amgen buys out Astellas Japanese joint venture. Sun Piaoyang steps down as Hengrui chairman. Moderna-NIH and Inovio work on coronavirus vaccines.